Patents Assigned to Quest Diagnostics
  • Mass spectrometric determination of fatty acids
    Patent number: 11017991
    Abstract: The invention relates to the detection of fatty acids. In a particular aspect, the invention relates to methods for detecting very long chain fatty acids and branched chain fatty acids by mass spectrometry.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 25, 2021
    Assignee: Quest Diagnostics Investments Incoporated
    Inventor: Scott Goldman
  • MICRORNA PROFILING FOR DIAGNOSIS OF DYSPLASTIC NEVI AND MELANOMA
    Publication number: 20210147947
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • MLH1 METHYLATION ASSAY
    Publication number: 20210130871
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: January 4, 2021
    Publication date: May 6, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Feras Hantash
  • METHOD FOR DETECTING CYSTIC FIBROSIS
    Publication number: 20210130896
    Abstract: The present invention relates to methods for amplifying various regions of the cystic fibrosis transmembrane regulator (CFTR) gene. Methods are provided for amplifying one or all 27 exons of the CFTR gene and a portion of the CFTR promoter region in a single tube. The method can identify the presence or absence of CF deletions or insertions in a sample and assist in the diagnosis of a genetic predisposition to cystic fibrosis.
    Type: Application
    Filed: June 23, 2020
    Publication date: May 6, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Feras Hantash, Weimin Sun
  • Methods of detecting MLH1 methylation
    Patent number: 10982288
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: April 20, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Feras Hantash, Amber Donahue
  • Methods for quantitation of insulin and C-peptide
    Patent number: 10983108
    Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 20, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Dov Shiffman, Carmen Tong, James J. Devlin, Michael J. McPhaul
  • METHODS FOR DETECTING NOROVIRUS
    Publication number: 20210095352
    Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 1, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
  • CYSTIC FIBROSIS GENE MUTATIONS
    Publication number: 20210095344
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 1, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Matthew J. McGINNISS, Arlene M. BULLER, Franklin QUAN, Mei PENG, Weimin SUN
  • Analysis of amino acids in body fluid by liquid chromotography-mass spectrometry
    Patent number: 10962550
    Abstract: This disclosure provides methods for quantifying individual amino acids in various bodily fluids obtained from a human patient. Also provided are reference ranges for normal amino acid levels in the various bodily fluids (e.g., blood plasma, urine, cerebrospinal fluid, and saliva) and for various age groups (e.g., neonates, infants, children, and adults).
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: March 30, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Scott Goldman
  • Mass spectrometry of steroidal compounds in multiplexed patient samples
    Patent number: 10955424
    Abstract: The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 23, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Brett Holmquist, Nigel Clarke
  • Compositions and methods for detecting mutations in JAK2 nucleic acid
    Patent number: 10954569
    Abstract: The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 23, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Maher Albitar, Wanlong Ma
  • Method for detecting cystic fibrosis
    Patent number: 10947592
    Abstract: The present invention relates to methods for simultaneously determining the presence or absence of mutations, deletions, duplications and single nucleotide polymorphisms in a cystic fibrosis transmembrane regulator (CFTR) nucleic acid. Oligonucleotide primers and kits used to amplify regions of a CFTR nucleic acid for high throughput, massively parallel sequencing and methods of determining an individual's cystic fibrosis status are also disclosed.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 16, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Steven Patrick Rivera
  • Mass spectrometry assay for congenital adrenal hyperplasia
    Patent number: 10948501
    Abstract: Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 16, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amit Ghoshal, Nigel J. Clarke, Mildred M. Goldman
  • Lipoprotein analysis by differential charged-particle mobility
    Patent number: 10948503
    Abstract: The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: March 16, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Michael P. Caulfield, Richard E. Reitz, Shuguang Li, Gloria Kwangja Lee, Ronald Krauss, Patricia J. Blanche, W. Henry Benner, Earl Cornell
  • Methods for detecting vitamin D metabolites by mass spectrometry
    Patent number: 10935558
    Abstract: Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: March 2, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel J. Clarke, Brett Holmquist, Gloria Kwang-Ja Lee, Richard E. Reitz
  • Assay for detection of pathogenic strains
    Patent number: 10907218
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: February 2, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Erik P. Johnson
  • MPL MUTATIONS IN JAK2 V617F NEGATIVE PATIENTS WITH MYELOPROLIFERATIVE DISEASE
    Publication number: 20210011019
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Wanlong MA, Maher Albitar
  • Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer
    Patent number: 10890587
    Abstract: Methods and kits for detecting alternating spatial expression of PTEN and, optionally, SMAD4, CD44, and/or TP53 in colonic tumors are described. The methods and kits are useful for identifying a cancer stem cell (CSC)-like zone within a colonic tumor, identifying an adenoma-adenocarcinoma (Ad-ACA) transition zone in a colorectal cancer (CRC) tumor, identifying a CRC tumor that contains high-grade adenoma and/or early adenocarcinoma regions, identifying CSCs in a CRC tumor, diagnosing a subject with high-grade colon adenoma and/or early adenocarcinoma, and determining the likelihood that a colonic tumor in a subject will undergo invasive transformation if left untreated.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: January 12, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Daniel Jones, Kevin J. Arvai, Ya-Hsuan Hsu
  • MLH1 methylation assay
    Patent number: 10883138
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter C region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 5, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Feras Hantash
  • Kits for detecting nucleic acid
    Patent number: 10876175
    Abstract: Disclosed is a method for determining the presence of Mycobacterium avium complex nucleic acids in a biological sample. In particular, the mig gene of M. avium and the DT1 gene of M. intracellulare are detected, preferably following amplification. In addition, the method distinguishes between species of M. avium and M. intracellulare. Also described are oligonucleotides that can be used as primers to amplify target genes such as mig and DT1 genes and as probes as well as kits containing the oligonucleotide.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: December 29, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Edgar Ong, Maurice Exner